Clinical trial · Observational
The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province
NCT03478943CI-TRIAL-00045288unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progress free survival
- timeFrame
- 1 year
- measure
- Disease-free surviva
- timeFrame
- 1 year
Secondary outcomes (3)
- measure
- overall survival
- timeFrame
- 3 year
- measure
- Objective Response Rate
- timeFrame
- 1 year
- measure
- Disease Control Rate
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female patients . 2. Confirmed by Pathology or histology of Gastric cancer. 3. Patients should be voluntary to the trial and provide with signed informed consent. 4. The researchers believe patients can benefit from the study. Exclusion Criteria: 1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories. 2. Pregnant or lactating women. 3. Patients with Apatinib contraindications. 4. Patients of doctors considered unsuitable for the trial.
References
Publications (0)
Data not yet available
No reference posted for this study.